CLINICAL TRIAL: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATMENT WITH MOD AUTOLOGOU

临床试验：使用 MOD AUTOLOGOU 治疗慢性淋巴细胞白血病 (CLL)

• 批准号: 7950679
• 负责人: MALCOLM K. BRENNER
• 金额: $ 0.03万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7950679
• 关键词: Antigen Presentation; Autologous; CD40 Ligand; Cells; Chronic Lymphocytic Leukemia; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Data; Funding; Grant; Human; Immune response; Institution; Interleukin-2; Malignant - descriptor; Natural Killer Cells; Patients; Recruitment Activity; Research; Research Personnel; Resources; Safety; Source; Subcutaneous Injections; T-Lymphocyte; Treatment Protocols; United States National Institutes of Health; in vivo; leukemia; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. It is proposed that the ability of CD40 Ligand (CD40L) to enhance leukemia antigen presentation in vivo, to act as a co-stimulator molecule and to induce IL-2 release all serve to recruit both specific T cell and NK cell anti-leukemia effector mechanisms, which IL-2 is then able to further amplify.SPECIFIC AIMS¿1) To determine the safety of three to six subcutaneous (SC) injections of autologous malignant B cells from chronic lymphocytic leukemia (B-CLL) patients, which have been modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L). 2) To determine whether MHC- restricted or unrestricted anti-tumor immune responses are induced by SC injections of B-CLL cells which have been modified ex vivo to secrete hIL-2 and to express hCD40L.3) To obtain preliminary data on the anti-tumor effects of this treatment regimen.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 有人提出，CD 40配体（CD 40 L）增强体内白血病抗原递呈、充当共刺激分子和诱导IL-2释放的能力都有助于招募特异性T细胞和NK细胞抗白血病效应器机制，然后IL-2能够进一步放大该机制。1）为了确定来自慢性淋巴细胞白血病（B-CLL）患者的自体恶性B细胞的三至六次皮下（SC）注射的安全性，其已被离体修饰以分泌人白细胞介素-2（hIL-2）并表达人CD 40配体（hCD 40 L）。2)确定通过SC注射B-CLL细胞是否诱导MHC限制性或非限制性抗肿瘤免疫应答，所述B-CLL细胞已经离体修饰以分泌hIL-2并表达hCD 40 L。3）获得关于该治疗方案的抗肿瘤作用的初步数据。